Genetech Inc. (DNA); Biogen Idec Inc. (BIIB) – Promising Drug Falls Short
The drug Rituxan, which is marketed by both Genetech Inc. (DNA) and partner Biogen Idec Inc. (BIIB), has failed to make any headway in the fight against lupus, a disease affecting the immune system and targeting more than one million Americans each year. There has never been much progress toward a cure, and some felt that Rituxan would be that miracle. The medication is already approved as a treatment for rheumatoid arthritis and some types of cancer, but the hope - that Rituxan might be effective against lupus - has fallen through. While the companies realize the serious challenges in…